Onset of CMV infection or disease typically occurs within the first 6 months after transplantation, when the recipient is most heavily immunosuppressed. 1 Symptomatic CMV disease occurs in 20-60% of all transplant recipients and is a significant cause of morbidity and mortality in this population. 1, 3 Direct links exist between CMV disease and several clinical effects, including CMV syndrome, infection of the allograft, native tissue-invasive infections, and disseminated CMV disease. [2] [3] [4] [5] [6] [7] [8] Several indirect clinical effects also can be seen in renal transplant recipients with CMV disease. These include superinfection with bacterial, fungal, or parasitic organisms; malignancy; allograft rejection; transplant renal artery stenosis; and thrombotic microangiopathy.
1, 4-8 Both direct and indirect effects of CMV have been associated with an increased frequency of graft dysfunction and shortened overall graft survival. [4] [5] [6] [7] [8] The mortality rate of CMV-infected transplant recipients approaches nearly 90% if this infection is left untreated. [5] [6] [7] [8] In addition to added morbidity and mortality, CMV disease increases the cost of transplantation due to extended hospitalizations and use of expensive antiviral therapies for the first year after transplantation. 9, 10 Several factors may play a role in the development of CMV infection and disease in the solid-organ transplant population. Key among these are the serologic status of the donor and recipient and the degree of immunosuppression. By definition, seropositive recipients (R+) have been exposed to the virus before transplantation and are at risk of reactivating their own latent virus. In addition, the virus can be acquired from the transplanted tissue of a seropositive donor (D+). The highest risk is encountered by patients whose serologic status is donor positive/recipient negative (D+/R-). These patients had no exposure to the virus before the transplant procedure and therefore lack preexisting immunity to CMV. An estimated 60% of D+/Rpatients develop CMV disease without proper antiviral prophylaxis. 4 Conversely, recent evidence indicates that the donor positive/recipient positive (D+/R+) group may have the worst long-term graft and patient survival. 11 The reason for this not entirely clear, although it is likely that the D+/R+ patients may have exposure to multiple strains of the virus, resulting in a CMV superinfection. Donor negative/recipient positive (D-/R+) patients tend to have a low risk of developing CMV disease; however, the risk of viral reactivation always must be considered.
10, 11 Donor negative/recipient negative (D-/R-) patients have the lowest risk of developing disease unless the virus is acquired by another vector after transplantation. 12 The class, dosage, and duration of immunosuppressive therapy may influence the risk of developing CMV disease. Antilymphocyte antibody preparations-muromonab-CD3, antithymocyte globulin (ATG), and lymphocyte immune globulin-have been associated with an increased risk for CMV infection in patients after transplantation, especially high-risk patients (e.g., D+/R-). These agents bind to T lymphocytes and alter their activity in the blood. The anti-lymphocyte antibody preparations can increase CMV replication by two proposed mechanisms. First, latent CMV, lying dormant in host cells secondary to the activity of the cell-mediated arm of immunity, is free to replicate unopposed when T lymphocytes are eliminated. Second, antilymphocyte antibody-induced lysis of T lymphocytes causes release of intracellular cytokines, which can trigger CMV replication.
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At most transplant centers in the United States, the accepted CMV preventive strategy is administration of antiviral drugs after transplantation. 17 Despite these pharmacokinetic data, controversy exists over the appropriate dosage and duration of valganciclovir for CMV prophylaxis.
Valganciclovir is indicated for treatment of CMV retinitis in patients with acquired immunodeficiency syndrome and for prevention of CMV disease in high-risk recipients (e.g., D+/R-) of kidney, heart, or simultaneous kidneypancreas transplants. 18 Two published studies have evaluated valganciclovir for CMV prophylaxis in solid-organ transplant recipients. 19, 20 In 2003, a research group reported a 15-month retrospective analysis of the use of ganciclovir, valganciclovir, and acyclovir for CMV prophylaxis in recipients of kidney, kidney-pancreas, pancreas, and kidney-liver transplants. 19 The study involved 129 patients, of whom 68 received ganciclovir 1 g 3 times/day, 47 received valganciclovir 450 mg/day, and 14 received acyclovir 400 mg twice/day. Acyclovir was administered only to low-risk patients with D-/Rstatus. In all patients, antiviral prophylaxis was started postoperatively and continued for 3 months. The overall CMV disease rate was 14%. There was no difference in the CMV disease rate between those patients receiving ganciclovir versus valganciclovir (15% vs 17%; p=NS). Regardless of the antiviral agent used, in 17 of the 18 patients who developed CMV, the disease manifested after discontinuation of prophylaxis (median 8 wks, range 2-28 wks). Univariate analysis revealed that development of CMV disease correlated with several factors, including antilymphocyte antibody induction therapy, D+/R-serostatus, African-American ethnicity, age greater than 50 years, and receipt of cadaveric allografts. The authors concluded that valganciclovir was as effective as ganciclovir for CMV prophylaxis in solid-organ transplantation.
Data from the other study, reported in 2004, were critical elements of the Food and Drug Administration's (FDA's) decision to approve valganciclovir for CMV prophylaxis. This 12-month, multicenter study evaluated the safety and efficacy of ganciclovir and valganciclovir in 364 high-risk, D+/R-, solid-organ transplant recipients. 20 Patients were randomized to receive valganciclovir 900 mg/day (239 patients) or ganciclovir 1 g 3 times/day (125 patients). Antiviral prophylaxis was started within 10 days of transplantation and continued for 100 days. At 12 months, the frequency of CMV disease was 17.2% in the valganciclovir group and 18.4% in the ganciclovir group (p=NS). The most common adverse events associated with valganciclovir were hematologic effects, including leukopenia, neutropenia, anemia, and thrombocytopenia. This analysis showed valganciclovir to be an effective and safe alternative to ganciclovir for CMV prophylaxis in high-risk, solid-organ transplant recipients. were used on a patient-specific basis. Tacrolimus was started at 0.05 mg/kg twice/day and adjusted to achieve whole blood trough concentrations of 8-12 ng/ml at months 0-6 and 6-10 ng/ml thereafter. Mycophenolate mofetil was started at 1 g twice/day and adjusted in those patients intolerant to the agent's gastrointestinal or hematologic adverse effects. Corticosteroids were started on day 0 with methylprednisolone 200 mg/day, followed by a rapid taper to prednisone 20 mg/day by postoperative day 5, and a further taper to prednisone 5 mg/day by 2-3 months after surgery. A rapid steroidwithdrawal protocol was used in six (10.3%) patients, with corticosteroids being completely withdrawn by postoperative day 5.
Methods
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Results
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All patients who received cadaveric renal transplants were administered ATG, as were all African-Americans (44.8%), all patients receiving a rapid steroid-withdrawal protocol, and all recipients of living donor kidneys with a prior history of renal transplantation. Transplant surgeons also administered ATG at their own discretion to some patients (22.4%) not meeting the above criteria. Standard ATG therapy consisted of 1-1.5 mg/kg for three doses. In patients experiencing delayed graft function, more than three doses were generally used, with a maximum cumulative dose of 6.5 mg/kg.
Prophylactic Regimens
Nearly all D-/R-patients received acyclovir 400 mg 3 times/day for prevention of herpes simplex virus infections (8 patients); however, one patient in this group was treated with valganciclovir. All other patients received valganciclovir 450 mg/day for CMV prophylaxis (49 patients). Thus, a total of 50 patients received valganciclovir. The goal duration of antiviral prophylaxis was for 6 months after transplantation. Trimethoprim-sulfamethoxazole, nystatin suspension, and antacids also were administered during the immediate period after transplantation. Atovaquone was substituted for trimethoprim-sulfamethoxazole in patients with a history of sulfa allergy or glucose-6-phosphate dehydrogenase deficiency.
Frequency of CMV Disease
The overall frequency of CMV disease at 1 year after transplantation was 5.2% (three of 58 patients). Each of these three patients was diagnosed with noninvasive CMV viremia; in each case, histopathologic testing confirmed the absence of tissue-invasive disease. All of these three patients had D+/R-serostatus, were men, had received cadaveric kidneys, and had been treated with ATG induction therapy. One (1.7%) patient developed CMV disease during the initial 6-month prophylaxis period. The other two patients were diagnosed with CMV after completion of prophylaxis, 10 and 60 days after discontinuation of valganciclovir.
Two of the patients had secondary infections along with CMV disease, one with disseminated varicella zoster and the other with cryptococcus meningoencephalitis. All patients were treated successfully with a combination of intravenous ganciclovir and oral valganciclovir. The patient who developed the disease while receiving valganciclovir prophylaxis was treated with CMV hyperimmune globulin and foscarnet, for fear of ganciclovir resistance. At our institution, laboratory diagnosis of CMV resistance is laborious and time consuming; therefore, a clinical diagnosis of ganciclovir resistance is used whenever possible. This diagnosis is made when the patient does not show marked improvement or resolution of clinical symptoms after 14-21 days of intravenous ganciclovir therapy. Ganciclovir resistance was not observed in any of the diagnosed cases. To date, these patients have had no recurrent CMV episodes.
The median length of stay for treatment of CMV disease was 25 days (range 4-31 days). No graft losses or deaths occurred. A more prolonged hospital course was needed for patients with superinfections. None of these patients experienced acute rejection, with a mean follow-up of 17 months (range 10-23 mo). Among all of the 58 patients, only one patient experienced an acute rejection, which was treated successfully with pulse-dose steroids.
Adverse Events
The Naranjo nomogram, 21 a method for estimating the probability of adverse drug reactions, was used to assess drug-induced toxicities in the 50 patients receiving valganciclovir. The hematologic toxicities of valganciclovir were assessed at monthly intervals while the patients were receiving prophylaxis. The frequency of leukopenia that was possibly associated with valganciclovir was 28%, and the corresponding frequency of thrombocytopenia was 24%. The overall frequency of at least one hematologic event in a given patient was 29.3%.
As already stated, the goal duration of antiviral therapy was 6 months. Thirty-four (68%) patients receiving valganciclovir were able to complete 6 months of prophylaxis without the need for dosage reduction or early discontinuation. However, 10 (20%) patients required early discontinuation or dosage reduction secondary to severe, persistent leukopenia, thrombocytopenia, or diarrhea. In six (12%) patients, therapy was halted before 6 months because of physician discretion. These patients were not experiencing adverse events at the time of discontinuation. None of the patients requiring dosage reduction or early discontinuation of therapy developed CMV disease.
Discussion
This single-center, retrospective analysis of valganciclovir for CMV prophylaxis in renal transplant recipients revealed that the overall frequency of CMV disease at our institution was 5.2%. All instances of CMV disease were noninvasive. The frequency of CMV disease at our institution seems much lower than that reported in the analysis of valganciclovir published in 2003. 19 That study, which provided valganciclovir 450/day for 3 months, demonstrated a 17% frequency of CMV disease. However, the efficacy of valganciclovir in both of these analyses was excellent, especially given that, in general, symptomatic CMV disease occurs in 20-60% of all transplant recipients. The manufacturer of ATG reported that the overall frequency of CMV disease after ATG induction therapy is 13.4%, despite antiviral prophylaxis. 23 Some clinical studies have shown it to be as high as 30%. 24, 25 The low rate of CMV disease in ATG-treated patients receiving valganciclovir 450 mg/day for 6 months seems to be significant, especially given the increased risk for CMV disease associated with ATG administration.
It should be noted that 94.4% of patients in the 2003 analysis developed CMV disease after discontinuing antiviral prophylaxis (median of 8 wks). 19 One factor that might explain the difference in efficacy is the differing duration of antiviral prophylaxis (3 mo vs 6 mo). Several early ganciclovir trials demonstrated efficacy with 3 months of prophylaxis.
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A 3-month duration of therapy has been adopted into clinical practice at several transplant centers, secondary to the success of this regimen in the above-mentioned trials.
1, 2-4 One recent study showed that 87-97% of transplant centers surveyed administered antiviral prophylaxis for 100 days or less. 28 Although the FDA has approved the dosing regimen of valganciclovir 900 mg/day for 100 days, clinicians have yet to reach consensus on the most appropriate dosage and duration for CMV prophylaxis with this agent. However, given that the risk of CMV disease after transplantation is highest within the first 6 months, our protocol calls for continuation of antiviral prophylaxis for 6 months after transplantation.
1, 2 Neither analysis noted any CMV resistance, which may help support a 450 mg/day dosage.
The phase III clinical trial reported in 2004 demonstrated a 17.2% rate of CMV disease with valganciclovir in liver, kidney, kidney-pancreas, and heart transplant recipients with D+/Rserostatus. 20 This trial administered valganciclovir 900 mg/day for 100 days. The frequency of CMV disease in our D+/R-recipients was 30% (3 of 10 patients). Although this is a small sample size, it raises concerns about the most appropriate prophylaxis regimen for these individuals. It may be a combination of these two protocols: 900 mg/day for 6 months.
A research group demonstrated that the optimal valganciclovir regimen in lung transplant recipients was 900 mg/day for 180 days. 29 Further studies are needed to evaluate the efficacy of both valganciclovir 450 mg/day and 900 mg/day for 6 months in high-risk, D+/Rtransplant recipients of all organ types.
In our analysis, valganciclovir 450 mg/day was associated with a high degree of hematologic effects (29.3%). Leukopenia and thrombocytopenia were the most commonly observed adverse events. However, this high rate may reflect pharmacodynamic drug-drug interactions between valganciclovir and concomitantly administered immunosuppressive agents (e.g., ATG, mycophenolate mofetil, tacrolimus). The multicenter study reported in 2004 demonstrated that valganciclovir 900 mg/day had a hematologic adverse-event rate of 38% and a withdrawal rate of 14% (dosage reduction not noted). 20 In our analysis, 20% of patients required early discontinuation or dosage reduction secondary to severe, persistent leukopenia, thrombocytopenia, and/or diarrhea. This led us to conclude that patients receiving both valganciclovir and mycophenolate mofetil should be closely monitored for signs of hematologic and gastrointestinal adverse events.
Valganciclovir 450 mg/day is an expensive prophylactic regimen, with an average wholesale price of $906.30/month of therapy. 30 To continue prophylaxis therapy past 3 months, our patients (or their insurance companies) must absorb an additional cost of approximately $2700. However, the drug cost of valganciclovir 900 mg/day for 3 months is equivalent to the cost of valganciclovir 450 mg/day for 6 months. It can be argued that valganciclovir 450 mg/day for 6 months is well worth its cost, given the decrease in resource utilization associated with a decreased rate of CMV disease.
The cost of CMV-related admissions in renal transplant recipients was nearly $23,000 (1998 U.S. dollars)/patient admission. 10 A decreased CMV disease rate would justify the increased cost of 6 months of valganciclovir prophylaxis. However, a pharmacoeconomic analysis of the costs versus benefits of the 6-month prophylaxis regimen is warranted. Table 2 presents an analysis of the average wholesale prices for different valganciclovir prophylaxis regimens.
We acknowledge the limitations of our study. We collected data retrospectively; however, one analyzer conducted all data extractions from medical charts and computerized medical records, thus preventing variability among raters.
Another limitation is the absence of a control group. The trial reported in 2003 used patients who had received ganciclovir as a historic control group. 19 However, at our institution, that approach would have been impractical, due to changes made in our immunosuppressive and antiviral protocols after August 2001 (study initiation date). Before this date, we administered oral ganciclovir 1000 mg 3 times/day to our patients at risk of CMV disease (e.g., D+/R-, D+/R+. D-/R+), but our immunosuppressive regimen lacked induction therapy and consisted only of maintenance therapy with cyclosporine, mycophenolate mofetil, and steroids. Given the high degree of immunosuppression produced by our new immunosuppressive protocol, we felt that patients who had been treated with ganciclovir would not provide an adequate control group, as development of CMV disease is dependent on the degree of immunosuppression.
Conclusion
This single-center, retrospective analysis revealed that valganciclovir 450 mg/day for 6 months is effective for prophylaxis of CMV disease in renal transplant recipients. This is an important finding, given that no published studies have demonstrated the efficacy of 6 months of low-dose valganciclovir prophylaxis in renal transplant recipients. Despite a low daily dose, there was a high rate (20%) of dosage reductions and premature discontinuations secondary to adverse events. The relatively high rate (29.3%) of hematologic adverse events is very important, especially since this agent often is administered concomitantly with other drugs that produce similar adverse effects.
Cytomegalovirus continues to be the most problematic opportunistic infection in solidorgan transplant recipients, especially those at high risk for disease (e.g., recipients of ATG, D+/R-serostatus). Further clinical and pharmacoeconomic studies are necessary to establish the most appropriate dosage and duration of valganciclovir for CMV prophylaxis in all solid-organ transplant recipients with varying degrees of risk for CMV disease. 
